RavenQuest BioMed Inc.
RVVQF · OTC
10/31/2018 | 10/31/2017 | 10/31/2016 | 10/31/2015 | |
|---|---|---|---|---|
| Revenue | $1,257 | $112 | $0 | $0 |
| % Growth | 1,018.8% | – | – | – |
| Cost of Goods Sold | $455 | $98 | $0 | $0 |
| Gross Profit | $801 | $15 | $0 | $0 |
| % Margin | 63.7% | 13% | – | – |
| R&D Expenses | $80 | $0 | $0 | $0 |
| G&A Expenses | $10,238 | $634 | $80 | $79 |
| SG&A Expenses | $11,185 | $634 | $80 | $79 |
| Sales & Mktg Exp. | $947 | $0 | $0 | $0 |
| Other Operating Expenses | -$10,463 | $22 | $0 | $0 |
| Operating Expenses | $801 | $656 | $81 | $83 |
| Operating Income | -$17,176 | -$642 | -$71 | -$83 |
| % Margin | -1,366.4% | -571.4% | – | – |
| Other Income/Exp. Net | -$13,870 | -$2,659 | -$10 | $7 |
| Pre-Tax Income | -$31,046 | -$3,301 | -$81 | -$76 |
| Tax Expense | -$578 | $0 | $0 | $0 |
| Net Income | -$30,468 | -$3,301 | -$81 | -$76 |
| % Margin | -2,423.9% | -2,938.1% | – | – |
| EPS | -0.33 | -0.1 | -0.003 | -0.003 |
| % Growth | -230% | -3,471.4% | -7.7% | – |
| EPS Diluted | -0.33 | -0.1 | -0.003 | -0.003 |
| Weighted Avg Shares Out | 91,034 | 32,479 | 29,000 | 29,000 |
| Weighted Avg Shares Out Dil | 91,034 | 32,479 | 29,000 | 29,000 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1,904 | $147 | $0 | $0 |
| Depreciation & Amortization | $1,881 | $0 | $23 | $7 |
| EBITDA | -$27,261 | -$3,154 | -$81 | -$76 |
| % Margin | -2,168.7% | -2,807.3% | – | – |